Heritage Medical Systems and AbbVie Ventures took part in genome editing technology developer Caribou Biosciences' first funding round in five years.

Funds managed by BlackRock added $40m to the $60m supplied for the drug development technology developer by investors including Novo, Evotec and Bristol Myers Squibb in May.

UC Berkeley-founded genome editing technology developer Caribou Biosciences has completed its first funding round in five years.

BlackRock has joined the University of Dundee spinout’s series C round, following a $60m first close in May last year.

Xenotransplantation technology developer eGenesis took its total funding to $263m in a series C round backed by Bayer and Fresenius Medical Care.

GV returned for a series C round that helped the precision cancer medicine developer increase its overall funding to over $180m.

Xenotransplantation technology developer eGenesis has raised $125m in a series C round backed by Osage University Partners.

The Vertex Pharmaceuticals-backed genomic analytics platform developer has now raised approximately $88m in funding altogether.

China Unicom has helped the Shanghai Electric-backed computer chip developer close a series C round that will fund commercialisation and research and development.

GV returned to help heart disease drug developer Tenaya boost its overall funding to approximately $248m.